Tarsus Pharmaceuticals (NASDAQ:TARS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Tarsus Pharmaceuticals (NASDAQ:TARS) from a hold rating to a buy rating in a research note published on Saturday.

A number of other research firms have also recently issued reports on TARS. Zacks Research cut Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 25th. Guggenheim lifted their target price on Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Barclays initiated coverage on Tarsus Pharmaceuticals in a report on Monday, December 8th. They set an “overweight” rating and a $100.00 target price on the stock. Oppenheimer lifted their target price on Tarsus Pharmaceuticals from $95.00 to $105.00 and gave the stock an “outperform” rating in a report on Wednesday, February 25th. Finally, Lifesci Capital raised Tarsus Pharmaceuticals to a “strong-buy” rating in a report on Monday, March 16th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Tarsus Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $91.83.

Tarsus Pharmaceuticals Stock Performance

Shares of TARS opened at $70.19 on Friday. The business’s fifty day moving average price is $68.19 and its 200 day moving average price is $71.48. Tarsus Pharmaceuticals has a 12-month low of $38.51 and a 12-month high of $85.25. The stock has a market capitalization of $2.99 billion, a PE ratio of -43.33 and a beta of 0.63. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.85 and a quick ratio of 3.82.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings data on Monday, February 23rd. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.01). Tarsus Pharmaceuticals had a negative return on equity of 19.63% and a negative net margin of 14.72%.The firm had revenue of $151.67 million for the quarter, compared to the consensus estimate of $144.56 million. Equities research analysts forecast that Tarsus Pharmaceuticals will post -3.17 EPS for the current year.

Insider Transactions at Tarsus Pharmaceuticals

In related news, General Counsel Bryan Wahl sold 4,231 shares of Tarsus Pharmaceuticals stock in a transaction dated Thursday, March 19th. The stock was sold at an average price of $67.00, for a total transaction of $283,477.00. Following the transaction, the general counsel directly owned 63,959 shares of the company’s stock, valued at $4,285,253. The trade was a 6.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director William J. Phd Link sold 12,500 shares of Tarsus Pharmaceuticals stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $68.79, for a total value of $859,875.00. Following the completion of the transaction, the director directly owned 116,332 shares in the company, valued at $8,002,478.28. This represents a 9.70% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 79,391 shares of company stock valued at $5,432,035 in the last three months. 8.97% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the stock. Deep Track Capital LP boosted its position in Tarsus Pharmaceuticals by 71.4% during the 3rd quarter. Deep Track Capital LP now owns 3,000,000 shares of the company’s stock worth $178,290,000 after acquiring an additional 1,250,000 shares during the period. Janus Henderson Group PLC boosted its position in Tarsus Pharmaceuticals by 34.1% during the 4th quarter. Janus Henderson Group PLC now owns 1,930,325 shares of the company’s stock worth $158,062,000 after acquiring an additional 491,326 shares during the period. Norges Bank acquired a new stake in Tarsus Pharmaceuticals during the 2nd quarter worth about $19,095,000. M&T Bank Corp boosted its position in Tarsus Pharmaceuticals by 11,730.0% during the 4th quarter. M&T Bank Corp now owns 437,119 shares of the company’s stock worth $35,791,000 after acquiring an additional 433,424 shares during the period. Finally, MPM Bioimpact LLC acquired a new stake in Tarsus Pharmaceuticals during the 2nd quarter worth about $13,834,000. Hedge funds and other institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.